The cost-effectiveness of GLP-1-RAs varies by agent and patient group, but their long-term benefits and potential to minimize diabetes-related healthcare expenditures make them an affordable diabetes treatment option [105]. This evidence concerns the gene GCG and diabetes mellitus.